Tumor-associated macrophages and tumor cell antigens (TAM/TAA)

Tumor-associated macrophages (TAMs) and tumor cell antigens represent a dual-component focus in oncology, where the former constitutes a critical part of the immunosuppressive tumor microenvironment and the latter provides specific targets for direct tumor destruction. TAMs are a predominant leukocyte population in solid tumors that typically adopt a pro-tumorigenic M2-like phenotype, facilitating immune evasion, angiogenesis, and metastasis (Noy & Pollard, 2014). Tumor cell antigens, such as HER2, CEA, or MUC1, are proteins or carbohydrates expressed on the surface of cancer cells that serve as docking sites for targeted therapies like monoclonal antibodies and antibody-drug conjugates (Abbott & Ustoyev, 2019). Modern therapeutic strategies often attempt to bridge these two components, for instance, by using bispecific antibodies that engage TAMs to phagocytose cells expressing specific tumor antigens or by using CSF1R inhibitors to deplete TAMs while simultaneously administering antigen-targeted vaccines (Cassetta & Pollard, 2018). This combined approach is designed to dismantle the protective niche of the tumor while delivering a direct cytotoxic blow to the malignant cells. However, the high plasticity of macrophages and the inherent heterogeneity of antigen expression remain significant challenges for clinical efficacy (Mantovani et al., 2017).

Other names

TAMs and tumor antigensTumor microenvironment and tumor-specific antigensTAM-TAA axisMacrophage-tumor cell interface

Therapeutic strategies involve the depletion or phenotypic reprogramming of immunosuppressive M2-like macrophages (TAMs) within the tumor microenvironment, often in combination with monoclonal antibodies or CAR-T cells that target specific surface antigens on tumor cells to induce direct lysis or phagocytosis.